Table IV.
Univariate analysis for survival.
| Parameters | No. of patients | 2-year-OS (%) | HR (95% CI) | P-value |
|---|---|---|---|---|
| Age, years | ||||
| <65 | 21 | 53.4 | 1.29 (0.37–4.40) | 0.696 |
| ≥65 | 7 | 68.6 | ||
| Gender | ||||
| Male | 14 | 53.4 | 2.00 (0.66–6.59) | 0.218 |
| Female | 14 | 62.9 | ||
| ECOG-PS score | ||||
| 0 | 6 | 80.0 | 0.22 (0.10–1.19) | 0.100 |
| 1, 2 | 22 | 50.6 | ||
| KPS score | ||||
| 90, 100 | 18 | 54.6 | 0.47 (0.13–1.45) | 0.179 |
| ≤80 | 10 | 64.0 | ||
| CCI | ||||
| ≤7 | 9 | 71.1 | 1.19 (0.37–3.87) | 0.761 |
| >7 | 19 | 52.0 | ||
| Age-adjusted CCI | ||||
| ≤7 | 7 | 57.1 | 1.30 (0.38–4.71) | 0.661 |
| >7 | 21 | 58.3 | ||
| Metastatic status | ||||
| Single site | 8 | 87.5 | 0.29 (0.15–0.84) | 0.024 |
| Multiple sites | 20 | 20.0 | ||
| Treatment site | ||||
| Primary | 7 | 57.1 | 2.40 (0.78–11.53) | 0.116 |
| Metastatic | 21 | 59.9 |
OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status; KPS, Karnofsky performance status; CCI, Charlson Comorbidity Index.